Screener
MoonLake Immunotherapeutics MLTX Current ratio
Current ratio at other companies
Other financials
Where this comes from
Calculated from MoonLake Immunotherapeutics’s reported figures.
Based on the most recent quarter.
The source filing: MoonLake Immunotherapeutics’s 10-Q, filed May 11, 2026. Open the filing →
- Filed
- May 11, 2026, 8:55 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001821586-26-000007
FAQ
- What is MoonLake Immunotherapeutics's current ratio?
- MoonLake Immunotherapeutics (MLTX) reported current ratio of 8.6× in Q1 2026.
- How has MoonLake Immunotherapeutics's current ratio changed year-over-year?
- MoonLake Immunotherapeutics's current ratio decreased by 59.3% year-over-year, from 21.1× to 8.6×.
- What is the long-term trend for MoonLake Immunotherapeutics's current ratio?
- Over 5 years (2020 to 2025), MoonLake Immunotherapeutics's current ratio has grown at a -6.4% compound annual growth rate (CAGR), from 12.9× to 9.3×.
- What does current ratio mean?
- Current assets divided by current liabilities at the quarter end. Measures the company's ability to cover near-term obligations with near-term assets.
Ask your AI about MoonLake Immunotherapeutics's current ratio.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude